---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070344"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T17:54:35.576348+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics Q1 net loss $12.7M, cash $15.9M; RT-114 Phase 1 mid-2025

## Summary
- Net loss was $12.7M for Q1 2025 ($14.8M in Q1 2024); cash, equivalents and marketable securities fell to $15.9M from $27.6M at year-end.
- Preclinical data show RT-114 (oral bispecific GLP-1/GLP-2 agonist) bioequivalent to subcutaneous PG-102 with 111% relative bioavailability.
- Preclinical data also demonstrate oral semaglutide via RaniPill (RT-116) comparable to subcutaneous in bioavailability, PK, and weight loss.
- Phase 1 clinical trial for RT-114 treating obesity expected to begin mid-2025.
- R&D expenses decreased to $6.6M and G&A to $5.6M; contract revenue was $0.2M from evaluation services.

## SEC filing metadata
- accession: 0000950170-25-070344
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017025070344/0000950170-25-070344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017025070344/rani-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070344
- JSON: https://secwatch.observer/filing/0000950170-25-070344.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.